{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:37:05Z","timestamp":1782538625615,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejpb.2020.09.008","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T08:01:03Z","timestamp":1601020863000},"page":"241-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Analytical method development and comparability study for AmBisome\u00ae and generic Amphotericin B liposomal products"],"prefix":"10.1016","volume":"157","author":[{"given":"Yayuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhanakrishnan","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Schwendeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2020.09.008_b0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/mmy\/myv111","article-title":"Comparison between liposomal formulations of amphotericin B","volume":"54","author":"Adler-Moore","year":"2016","journal-title":"Sabouraudia"},{"key":"10.1016\/j.ejpb.2020.09.008_b0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0169-409X(96)00496-6","article-title":"Supramolecular lipidic drug delivery systems: From laboratory to clinic A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B","volume":"24","author":"Hillery","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2020.09.008_b0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1517\/14740338.2013.827168","article-title":"Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B","volume":"12","author":"Loo","year":"2013","journal-title":"Exp. Opin. Drug Saf."},{"key":"10.1016\/j.ejpb.2020.09.008_b0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1054-3589(08)60129-5","article-title":"Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development","volume":"44","author":"Groll","year":"1998","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.ejpb.2020.09.008_b0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1128\/AAC.00870-07","article-title":"Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products","volume":"52","author":"Olson","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2020.09.008_b0030","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of clinical translation of cancer nanomedicines\u2014lessons learned from successes and failures","volume":"52","author":"He","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejpb.2020.09.008_b0035","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2020.09.008_b0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome\u00ae): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2020.09.008_b0045","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/cid\/ciz064","article-title":"Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B","volume":"68","author":"Adler-Moore","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2020.09.008_b0050","unstructured":"I. Gilead Sciences, Gilead Sciences Announces Fourth Quarter and Full Year 2019 Financial Results, in, 2020."},{"key":"10.1016\/j.ejpb.2020.09.008_b0055","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/jps.21179","article-title":"Amphotericin B formulations and drug targeting","volume":"97","author":"Torrado","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.09.008_b0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/49.suppl_1.21","article-title":"Am Bisome: Lipsomal formulation, structure, mechanism of action and pre-clinical experience","volume":"49","author":"Adler-Moore","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2020.09.008_b0065","doi-asserted-by":"crossref","first-page":"e02383","DOI":"10.1128\/mBio.02383-17","article-title":"The viscoelastic properties of the fungal cell wall allow traffic of Am Bisome as intact liposome vesicles","volume":"9","author":"Walker","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.ejpb.2020.09.008_b0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/pharmaceutics12010029","article-title":"Lipid systems for the delivery of amphotericin B in antifungal therapy","volume":"12","author":"Faustino","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.09.008_b0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/mmy\/myu070","article-title":"Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice","volume":"53","author":"Olson","year":"2014","journal-title":"Sabouraudia"},{"key":"10.1016\/j.ejpb.2020.09.008_b0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2018.11.010","article-title":"Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome","volume":"134","author":"Tang","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.09.008_b0085","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08982109309150729","article-title":"Development, characterization, efficacy and mode of action of Am Bisome, a unilamellar liposomal formulation of amphotericin B","volume":"3","author":"Adler-Moore","year":"1993","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejpb.2020.09.008_b0090","article-title":"Different liposomal amphotericin B formulations for visceral leishmaniasis\u2013Author's reply","volume":"2","author":"Kshirsagar","year":"2014","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.ejpb.2020.09.008_b0095","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbrc.2015.06.177","article-title":"Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs","volume":"468","author":"Szebeni","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejpb.2020.09.008_b0100","unstructured":"FDA, Draft Guidance on Amphotericin B, in, 2016."},{"key":"10.1016\/j.ejpb.2020.09.008_b0105","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.36.10.2310","article-title":"Effects of the aggregation state of amphotericin B on its toxicity to mice","volume":"36","author":"Barwicz","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2020.09.008_b0110","unstructured":"AmBisome\u00ae package insert., in."},{"key":"10.1016\/j.ejpb.2020.09.008_b0115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1208\/s12248-016-9958-2","article-title":"Development of a flow-through USP-4 apparatus drug release assay to evaluate doxorubicin liposomes","volume":"19","author":"Yuan","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2020.09.008_b0120","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/591325","article-title":"Liposome technology for industrial purposes","volume":"2011","author":"Wagner","year":"2011","journal-title":"J. Drug Delivery"},{"key":"10.1016\/j.ejpb.2020.09.008_b0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejps.2010.07.009","article-title":"A thermosensitive vaginal gel formulation with HP\u03b3CD for the pH-dependent release and solubilization of amphotericin B","volume":"41","author":"Kim","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.09.008_b0130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1081\/DDC-120037484","article-title":"Characterization of amphotericin B liposome formulations","volume":"30","author":"Manosroi","year":"2004","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2020.09.008_b0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0005-2736(93)90246-V","article-title":"Temperature effects on the aggregation state and activity of amphotericin B","volume":"1152","author":"Lambing","year":"1993","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembr."},{"key":"10.1016\/j.ejpb.2020.09.008_b0140","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1021\/bi962894z","article-title":"The formation of amphotericin B ion channels in lipid bilayers","volume":"36","author":"Fujii","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejpb.2020.09.008_b0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-3659(02)00347-4","article-title":"Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly (ethylene oxide)-block\u2013poly (N-hexyl-l-aspartamide)-acyl conjugate micelles: effects of acyl chain length","volume":"87","author":"Adams","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2020.09.008_b0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/chir.22142","article-title":"Circular Dichroism Studies on Intermolecular Interactions of Amphotericin B in Ionic Liquid-Rich Environments","volume":"25","author":"Jameson","year":"2013","journal-title":"Chirality"},{"key":"10.1016\/j.ejpb.2020.09.008_b0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/107175499266995","article-title":"Determination of the relative toxicity of amphotericin B formulations: a red blood cell potassium release assay","volume":"6","author":"Jensen","year":"1999","journal-title":"Drug Delivery"},{"key":"10.1016\/j.ejpb.2020.09.008_b0160","unstructured":"CLSI, M27-A2. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - Second Edition, in, Clinical and Laboratory Standards Institute, 2002."},{"key":"10.1016\/j.ejpb.2020.09.008_b0165","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpha.2015.11.005","article-title":"Methods for in vitro evaluating antimicrobial activity: a review","volume":"6","author":"Balouiri","year":"2016","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.ejpb.2020.09.008_b0170","unstructured":"Phosome\u00ae package insert, in."},{"key":"10.1016\/j.ejpb.2020.09.008_b0175","unstructured":"Amphonex\u00ae package insert, in."},{"key":"10.1016\/j.ejpb.2020.09.008_b0180","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1208\/s12248-017-0084-6","article-title":"How has CDER prepared for the nano revolution? A review of risk assessment, regulatory research, and guidance activities","volume":"19","author":"Tyner","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2020.09.008_b0185","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2018.09.001","article-title":"Drug nanocrystallisation within liposomes","volume":"288","author":"Li","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2020.09.008_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118603","article-title":"Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation","volume":"569","author":"Van Haute","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.09.008_b0195","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/2211738501999131118125018","article-title":"Amphotericin B formulations\u2013the possibility of generic competition","volume":"1","author":"Serrano","year":"2013","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.ejpb.2020.09.008_b0200","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijpharm.2019.04.052","article-title":"Critical process parameters in manufacturing of liposomal formulations of amphotericin B","volume":"565","author":"Rivnay","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.09.008_b0205","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/pharmaceutics11110589","article-title":"Preparationcharacterization, and in vivo pharmacokinetic study of the supercritical fluid-processed liposomal amphotericin B","volume":"11","author":"Lim","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.09.008_b0210","first-page":"301","article-title":"Optimizing efficacy of Amphotericin B through nanomodification","volume":"2","author":"Barratt","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2020.09.008_b0215","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5639\/gabij.2013.0202.022","article-title":"Access to liposomal generic formulations: beyond Am Bisome and Doxil\/Caelyx","volume":"2","author":"Gaspani","year":"2013","journal-title":"GaBi J"},{"key":"10.1016\/j.ejpb.2020.09.008_b0220","series-title":"Advancing Product Quality: A Summary of the SECOND FDA\/PQRI Conference","author":"Lawrence","year":"2016"},{"key":"10.1016\/j.ejpb.2020.09.008_b0225","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2020.09.008_b0230","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1166\/jcsb.2012.1020","article-title":"Preparation, characterization and applications of liposomes: state of the art","volume":"1","author":"Laouini","year":"2012","journal-title":"J. Colloid Sci. Biotechnol."},{"key":"10.1016\/j.ejpb.2020.09.008_b0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49","author":"Deray","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2020.09.008_b0240","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficacy and toxicities","volume":"27","author":"Wong-Beringer","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2020.09.008_b0245","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/22.2.315","article-title":"Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS","volume":"22","author":"Sharkey","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2020.09.008_b0250","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2020.09.008_b0255","doi-asserted-by":"crossref","unstructured":"B. \u010ceh, M. Winterhalter, P.M. Frederik, J.J. Vallner, D.D. Lasic, Stealth\u00ae liposomes: from theory to product, Adv. Drug Delivery Rev. 24 (1997) 165\u2013177.","DOI":"10.1016\/S0169-409X(96)00456-5"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120302848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120302848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:42:12Z","timestamp":1760546532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641120302848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":51,"alternative-id":["S0939641120302848"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.09.008","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analytical method development and comparability study for AmBisome\u00ae and generic Amphotericin B liposomal products","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}